Proteasome subunit beta type-2 (PSMB2) (PSMB2)

The Proteasome subunit beta type-2 (PSMB2) is a core catalytic component of the 20S proteasome, the central enzyme of the ubiquitin-proteasome system (UPS) responsible for the degradation of intracellular proteins [UniProt: P49721]. PSMB2 specifically mediates the trypsin-like activity of the proteasome, cleaving peptide bonds after basic amino acid residues [PubMed: 16169920]. This subunit plays a vital role in maintaining cellular protein homeostasis by regulating the levels of proteins involved in the cell cycle, signal transduction, and apoptosis [PubMed: 21149454]. In clinical practice, PSMB2 is a key target in the treatment of multiple myeloma and mantle cell lymphoma, as these cancers are highly dependent on proteasome function for survival [DrugBank: DB00188]. While first-generation inhibitors like bortezomib primarily target the β5 subunit, they also inhibit β2, and newer agents like marizomib are designed to target all three catalytic subunits (β1, β2, and β5) to overcome drug resistance [PubMed: 22496081]. However, systemic inhibition of PSMB2 and its counterparts can lead to significant side effects, including peripheral neuropathy and myelosuppression, which remain major challenges in therapy [PubMed: 19147507].

Other names

PSMB2Proteasome subunit ZMacropain subunit C7-IProteasome component C7-I20S proteasome subunit beta-2

Inhibition of the trypsin-like proteolytic activity of the 20S proteasome complex.